UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~January~~March 2127, 2026

Autolus Therapeutics plc

(Exact name of registrant as specified in its Charter)


England and Wales	001-38547		Not applicable
(State or other jurisdiction of incorporation or organization)	(Commission File Number)		(I.R.S. Employer Identification No.)

The Mediaworks
191 Wood Lane
London		W12 7FP
United Kingdom
(Address of principal executive offices)(Zip Code)

(44) 20		3829 6230
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share	AUTL	The Nasdaq Global Select Market
Ordinary shares, nominal value $0.000042 per share*	*	The Nasdaq Stock Market LLC*


*						Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Select Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 12.0102 Results ~~Entry~~of ~~into~~Operations aand ~~Material~~Financial ~~Definitive Agreement~~Conditions.

On ~~January~~March 2127, 2026, Autolus ~~Limited, a wholly owned subsidiary of Autolus~~ Therapeutics plc (the “~~registrant”, and together with Autolus Limited, the “~~Company”), ~~entered~~announced ~~into~~its afinancial ~~Master~~results ~~Service Agreement with AGC Biologics S.p.A (“AGC”)~~ for the ~~manufacture~~year ~~and~~ended ~~supply~~December of31, ~~lentiviral~~2025 ~~vector~~and ~~(the~~provided ~~“Agreement”),~~ a ~~raw~~corporate ~~material~~update. ~~which~~A iscopy ~~critical~~of ~~for~~ the ~~Company’s~~press ~~manufacture~~release ofis ~~CAR-T~~being ~~products~~furnished ~~for~~as ~~clinical~~Exhibit ~~and commercial use~~99.1 ~~The~~hereto ~~Agreement replaces~~ and ~~supersedes~~is ~~the~~incorporated ~~prior~~by ~~arrangement~~reference ~~between the Company and AGC, pursuant to which AGC has provided similar products and services~~herein.

The ~~Agreement~~information ~~sets forth the general terms and conditions applicable to AGC’s provision of products and services to the Company; specific projects will be set forth~~ in ~~individual~~this ~~work~~Item ~~orders executed separately by the parties~~2. ~~The Agreement contains customary provisions regarding order placement and fulfillment~~02, ~~governance,~~including ~~regulatory~~Exhibit ~~support,~~99.1 ~~change~~attached ~~management~~hereto, ~~risk~~is ~~allocation,~~being ~~intellectual~~furnished ~~property,~~ and ~~confidentiality.~~shall ~~The~~not ~~Agreement~~be ~~runs~~deemed “filed” for apurposes ~~fixed term~~ of ~~ten~~Section ~~years,~~18 ~~and~~of ~~may~~the beSecurities ~~terminated~~Exchange byAct ~~either~~of ~~party for default~~1934, oras byamended (the ~~Company~~“Exchange ~~upon~~Act”), ~~written~~or ~~notice~~otherwise (subject, ~~in the latter case,~~ to the ~~payment~~liabilities of ~~certain~~that ~~fees by the Company)~~section. The ~~Agreement~~information iscontained ~~non-exclusive~~herein ~~with~~and ~~respect~~in tothe ~~each~~accompanying ~~party.~~exhibit ~~However,~~is ~~under~~not ~~the~~incorporated ~~Agreement~~by ~~and~~reference ~~the~~in ~~initial~~any ~~statement~~filing of ~~work thereunder,~~ the Company ~~has~~under ~~committed~~the toSecurities ~~purchase~~Act ~~a minimum~~ of 141933, ~~batches~~as ofamended ~~lentiviral vector during~~ (the ~~first~~“Securities ~~two~~Act”), ~~calendar~~or ~~years of~~ the ~~term~~Exchange Act, ~~and~~whether tomade ~~purchase~~before aor ~~minimum~~after ~~value~~the ofdate ~~EUR~~hereof, 25regardless ~~million~~ of ~~products~~any ~~and~~general ~~services~~incorporation ~~during~~language ~~the~~in ~~subsequent~~such ~~five-year~~filing, ~~period.~~except ~~The~~as ~~Agreement~~shall ~~also~~be ~~provides~~expressly ~~AGC~~set ~~with~~forth ~~the~~by ~~first~~specific ~~right~~reference ~~to negotiate with the Company regarding the provision of new manufacturing activities~~ in ~~relation~~such ~~to the Company’s obecabtagene autoleucel, or obe-cel, product~~filing.

The foregoing summary of the material terms of the Master Service Agreement does not purport to be complete and is qualified in its entirety by reference to such Master Service Agreement, which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending March 31, 2026. Portions of the Agreement may be omitted pursuant to Item ~~601(b)(10)(iv) or Item 601(a)(5) of~~ 7.01 Regulation ~~S-K~~FD ~~under the Securities Exchange Act of 1934, as amended~~Disclosure.

In connection with its conference call on March 27, 2026 to discuss its results for the year ended December 31, 2025, the Company will utilize an updated corporate presentation, a copy of which is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.2 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

d) Exhibits


Exhibit No.						Description of Exhibit

99.1						Press release dated March 2 7, 2 026
99.2						Corporate Presentation dated March 27 , 202 6
104						Cover Page Interactive Date File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		AUTOLUS THERAPEUTICS PLC
Dated: January 26, 2026	By:	/s/Christian Itin, Ph.D.
Dated: March 27, 2026	By:	/s/Christian Itin, Ph.D.
		Name: Christian Itin, Ph.D.
		Title: Chief Executive Officer

Filing Compare · Autolus Therapeutics plc